Log in

OTCMKTS:BRTX - BioRestorative Therapies Stock Price, Forecast & News

$0.02
0.00 (0.00 %)
(As of 12/16/2019 04:44 AM ET)
Today's Range
$0.01
Now: $0.02
$0.02
50-Day Range
$0.02
MA: $0.08
$0.17
52-Week Range
$0.01
Now: $0.02
$0.94
Volume2.75 million shs
Average Volume808,774 shs
Market Capitalization$584,440.00
P/E RatioN/A
Dividend YieldN/A
Beta0.07
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BRTX
CUSIPN/A
CIKN/A
Phone631-760-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$110,000.00
Book Value($0.68) per share

Profitability

Net Income$-12,520,000.00
Net Margins-13,124.41%

Miscellaneous

Employees8
Market Cap$584,440.00
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive BRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BRTX and its competitors with MarketBeat's FREE daily newsletter.


BioRestorative Therapies (OTCMKTS:BRTX) Frequently Asked Questions

What is BioRestorative Therapies' stock symbol?

BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."

When is BioRestorative Therapies' next earnings date?

BioRestorative Therapies is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for BioRestorative Therapies.

Has BioRestorative Therapies been receiving favorable news coverage?

Media coverage about BRTX stock has trended negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioRestorative Therapies earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for BioRestorative Therapies.

Who are some of BioRestorative Therapies' key competitors?

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include American Graphite Technologies (AGIN), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Baidu (BIDU), Cronos Group (CRON), JD.Com (JD), Ligand Pharmaceuticals (LGND), Marvell Technology Group (MRVL), Novavax (NVAX) and OrganiGram (OGI).

Who are BioRestorative Therapies' key executives?

BioRestorative Therapies' management team includes the folowing people:
  • Mr. Mark R. Weinreb, Chairman, CEO & Pres (Age 66)
  • Mr. Robert Paccasassi, VP of Quality & Compliance (Age 50)
  • Ms. Mandy D. Clyde, VP of Operations & Sec. (Age 37)
  • Dr. Wayne J. Olan, Clinical Director of Regenerative & Spine Program and Member of Scientific Advisory Board
  • Mr. Lance Alstodt, Exec. VP & Chief Strategy Officer (Age 48)

How do I buy shares of BioRestorative Therapies?

Shares of BRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioRestorative Therapies' stock price today?

One share of BRTX stock can currently be purchased for approximately $0.02.

How big of a company is BioRestorative Therapies?

BioRestorative Therapies has a market capitalization of $584,440.00 and generates $110,000.00 in revenue each year. BioRestorative Therapies employs 8 workers across the globe.View Additional Information About BioRestorative Therapies.

What is BioRestorative Therapies' official website?

The official website for BioRestorative Therapies is http://www.biorestorative.com/.

How can I contact BioRestorative Therapies?

BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at 631-760-8100 or via email at [email protected]


MarketBeat Community Rating for BioRestorative Therapies (OTCMKTS BRTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about BioRestorative Therapies and other stocks. Vote "Outperform" if you believe BRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel